menu
{ "item_title" : "Drug Discovery in Cancer Epigenetics", "item_author" : [" Gerda Egger", "Paola Arimondo "], "item_description" : "Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic.", "item_img_path" : "https://covers2.booksamillion.com/covers/bam/0/12/802/208/0128022086_b.jpg", "price_data" : { "retail_price" : "170.00", "online_price" : "170.00", "our_price" : "170.00", "club_price" : "170.00", "savings_pct" : "0", "savings_amt" : "0.00", "club_savings_pct" : "0", "club_savings_amt" : "0.00", "discount_pct" : "10", "store_price" : "" } }
Drug Discovery in Cancer Epigenetics|Gerda Egger

Drug Discovery in Cancer Epigenetics

local_shippingShip to Me
On Order. Usually ships in 2-4 weeks
FREE Shipping for Club Members help

Overview

Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic.

This item is Non-Returnable

Details

  • ISBN-13: 9780128022085
  • ISBN-10: 0128022086
  • Publisher: Academic Press
  • Publish Date: December 2015
  • Dimensions: 9.3 x 7.4 x 1.1 inches
  • Shipping Weight: 2.65 pounds
  • Page Count: 498

Related Categories

You May Also Like...

    1

BAM Customer Reviews